Funding for this research was provided by:
National Cancer Institute (P30CA014089)
Dhont Family Foundation
Gloria Borges WunderGlo Foundation-The Wunder Project
San Pedro Peninsula Cancer Guild
Daniel Butler Research Fund
Call to Cure Research Fund
Text and Data Mining valid from 2019-01-16
First Online: 16 January 2019
Compliance with Ethical Standards
: Francesca Battaglin has received honoraria for lectures from Eli Lilly and Company, and travel/accommodation support from Bayer and Amgen Inc. Heinz-Josef Lenz has received clinical trial financial support from Merck Serono and Roche, honoraria for advisory board membership and lectures from Bayer, Boehringer Ingelheim, Genentech, Pfizer, Merck Serono and Roche, and travel/accommodation support from Bayer, Merck Serono and Roche. Fotios Loupakis has received travel/accommodation support from Amgen Inc., Merck Serono and Roche. Sara Lonardi has received research funding from Merck Serono and Amgen Inc., honoraria for consulting/advisory roles from Amgen Inc., Bayer Healthcare, Merck Serono and Eli Lilly and Company, and honoraria for speakers’ bureau from Eli Lilly and Company, Bristol-Myers Squibb and Roche. Alberto Puccini, Nagore I. Marín-Ramos, Francesca Bergamo and Marta Schirripa have no conflicts of interest that are directly relevant to the content of this manuscript.
: This manuscript was partly supported by the National Cancer Institute (grant number P30CA014089), the Gloria Borges WunderGlo Foundation–The Wunder Project, the Dhont Family Foundation, the San Pedro Peninsula Cancer Guild, the Daniel Butler Research Fund, and the Call to Cure Research Fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.